Adacolumn in Refractory UC Patients Trial

Ulcerative Colitis, Active Moderate Clinical Trial

— ART  

Official title:

Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01481142
• Other study ID #: Ada-UC-08-102
• Status: Completed
• Phase: Phase 4
• First received: November 24, 2011
• Last updated: October 16, 2015
• Start date: October 2011
• Est. completion date: July 2015

Study information

• Verified date: October 2015
• Source: Otsuka Pharmaceutical Europe Ltd
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The objectives of the study are to observe and document the efficacy and safety of 5 or more Adacolumn treatments, administered once weekly over 5 or more weeks, in a specific subset of ulcerative colitis patients. The patient subset of interest is those with moderate/severe, steroid-dependent, active ulcerative colitis with insufficient response or intolerance to immunosuppressants and/or biological agents.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: July 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients enrolled into the study will be between 18 and 75 years old and have moderate to severe, steroid-dependent, active ulcerative colitis documented by clinical symptoms, endoscopic findings and histology. Patients will have an ulcerative colitis clinical activity (CAI) of =6 and an endoscopic activity index (EAI) of =4. Patients will have an insufficient response or intolerance to immunosuppressants and/or biological treatment agents. Patients are required to have adequate peripheral venous access to allow completion of apheresis treatment.

Exclusion Criteria:

• A patient will be excluded from the study if he/she meets any of the following criteria:

1. Is febrile (body temperature >38ºC).

2. Has evidence of toxic megacolon.

3. Has known obstructive disease of the gastrointestinal system.

4. Is anticipated to need surgery within the next 24 weeks.

5. Has a history of hypersensitivity reaction associated with an apheresis procedure or an intolerance to apheresis procedures.

6. Has proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis.

7. Has a history of allergic reaction to heparin or of heparin-induced thrombocytopenia.

8. Has a known infection with enteric pathogens, pathogenic ova or parasites, or a positive test for cytomegalovirus.

9. Has symptomatic hypotension.

10. Has a history of physical findings consistent with a cerebrovascular accident.

11. Has a history of myocardial infarction or unstable angina within the previous 6 months.

12. Has undergone coronary artery bypass graft surgery or angioplasty within the previous 6 months.

13. Has congestive heart failure (New York Heart Association Class III or IV).

14. Has a prosthetic heart valve, pacemaker or other permanent implant.

15. Has severe cardiovascular or peripheral vascular disease.

16. Has liver disease defined as levels of aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) or alkaline phosphatase of greater than 2.5 × the upper limit of the normal range for the laboratory performing the test.

17. Has a history of cirrhosis.

18. Has a known bleeding disorder (prothrombin time [PT] or partial thromboplastin time [PTT] greater than 1.5 × the upper limit of the normal range for the laboratory performing the test) or requires concomitant anticoagulant therapy for purposes other than apheresis treatment.

19. Has a prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis.

20. Has a known infection with hepatitis B or C or human immunodeficiency virus.

21. Has abnormal haematology parameters defined as severe anaemia with haemoglobin <8.5 g/dL, white blood cell count <3500/µL or granulocyte count <2000/µL.

22. Has a fibrinogen level >700 mg/dL.

23. Has renal insufficiency, defined as a serum creatinine level greater than 150% of the upper limit of the normal range for the laboratory performing the test.

24. Has had major surgery within the previous 6 weeks.

25. Has any of the following types of infection:

• An active infection within 4 weeks of successful completion of antibiotic treatment for a bacterial infection.

• Febrile viral infection within the 4 weeks prior to entry into the study.

• Systemic fungal infection that required therapy which was completed within the 12 weeks prior to entry into the study.

26. Current drug or alcohol abuse.

27. Is pregnant, lactating or planning to become pregnant during the study.

28. Has used an investigational medicinal product, biologic agent or device within the last 30 days.

29. Adults lacking capacity who are unable to give consent by themselves due to physical and or mental incapacity.

30. Prisoners and patients who have undergone psychiatric treatment.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis, Active Moderate

Intervention

Device:
• (GMA) Adsorptive Apheresis
Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.

Locations

Country	Name	City	State
France	Clinique Universitaire d'Hépato-Gastroentérologie	Grenoble cedex

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Pharmaceutical Europe Ltd

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary efficacy endpoint is the ulcerative colitis remission rate at Week 12, defined as a CAI (Rachmilewitz) score of =4.		12 weeks	Yes
Secondary	Ulcerative colitis response rate at Week 12, with response defined as a reduction in CAI of =3.		12 weeks	No
Secondary	Response and remission rates at Weeks 24 and 48		12 weeks	No
Secondary	Change from Baseline in CAI at Weeks 12, 24 and 48		12 weeks, 24 weeks and 48 weeks	No
Secondary	Change from Baseline in EAI at Week 12		12 weeks	No
Secondary	Time to remission and response		Baseline	No
Secondary	The proportion of patients reaching steroid-free remission/steroid-free response at any visit and by visit at Weeks 12, 24 and 48.		12 weeks, 24 weeks and 48 weeks	No
Secondary	Time to steroid-free remission and response.		Baseline	No
Secondary	Colectomy rate at Week 96		96 weeks	No
Secondary	Change from Baseline in concomitant medication (steroid) dose at Weeks 12, 24 and 48.		12 weeks, 24 weeks and 48 weeks	No
Secondary	Quality of life changes based on the Short Health Scale for ulcerative colitis at Weeks 5, 12, 24 and 48.		5 weeks, 12 weeks, 24 weeks and 48 weeks	No